The characteristic muscle weakness in myasthenia gravis (MG) is caused by antibodies against target molecules the neuromuscular junction. Here, Nils Gilhus and colleagues review how these antibodies and other biomarkers can be used to guide MG subgroup classification and treatment, as well as the best tests to detect these antibodies. Moreover, they discuss how the various antibodies are involved in MG pathogenesis.
- Nils Erik Gilhus
- Geir Olve Skeie
- Socrates Tzartos
